Galera Therapeutics, Inc. financial data

Symbol
GRTX on OTC
Industry
Pharmaceutical Preparations
Location
101 Lindenwood Drive, Suite 225, Malvern, PA
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-K - Q4 2024 - Mar 31, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 685 % +104%
Debt-to-equity -109 % +20.2%
Return On Equity 13.5 % -73.2%
Return On Assets -138 % -0.23%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 75.5M shares +38.7%
Common Stock, Shares, Outstanding 75.5M shares +38.7%
Entity Public Float 4.9M USD -96.2%
Common Stock, Value, Issued 75K USD +38.9%
Weighted Average Number of Shares Outstanding, Basic 54.6M shares +22.6%
Weighted Average Number of Shares Outstanding, Diluted 54.6M shares +22.6%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 3.15M USD -86.9%
General and Administrative Expense 11M USD -51.8%
Operating Income (Loss) -20.2M USD +59.1%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -5.78M USD +61.6%
Income Tax Expense (Benefit) -203K USD
Net Income (Loss) Attributable to Parent -19M USD +67.9%
Earnings Per Share, Basic -0.34 USD/shares +74.4%
Earnings Per Share, Diluted -0.34 USD/shares +74.4%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 8.29M USD -54.6%
Assets, Current 10M USD -53.8%
Property, Plant and Equipment, Net 0 USD -100%
Operating Lease, Right-of-Use Asset 0 USD -100%
Goodwill 0 USD -100%
Other Assets, Noncurrent 100K USD +11.1%
Assets 10.1M USD -61.4%
Accounts Payable, Current 1.28M USD -7.27%
Accrued Liabilities, Current 391K USD -88.7%
Liabilities, Current 1.67M USD -66.4%
Operating Lease, Liability, Noncurrent 0 USD -100%
Liabilities 154M USD -2.26%
Accumulated Other Comprehensive Income (Loss), Net of Tax 0 USD
Retained Earnings (Accumulated Deficit) -456M USD -4.33%
Stockholders' Equity Attributable to Parent -148M USD -12.8%
Liabilities and Equity 10.1M USD -61.4%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -4.79M USD +58.9%
Net Cash Provided by (Used in) Financing Activities 0 USD -100%
Net Cash Provided by (Used in) Investing Activities 0 USD -100%
Common Stock, Shares Authorized 200M shares 0%
Common Stock, Shares, Issued 75.5M shares +38.7%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -4.79M USD -122%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 8.29M USD -54.6%
Deferred Tax Assets, Valuation Allowance 75.8M USD +3.97%
Deferred Tax Assets, Gross 76M USD +3.11%
Operating Lease, Liability 0 USD -100%
Payments to Acquire Property, Plant, and Equipment 0 USD -100%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -19M USD +67.9%
Lessee, Operating Lease, Liability, to be Paid 1.4M USD -12.1%
Property, Plant and Equipment, Gross 0 USD -100%
Operating Lease, Liability, Current 0 USD -100%
Lessee, Operating Lease, Liability, to be Paid, Year Two 220K USD +1.38%
Lessee, Operating Lease, Liability, to be Paid, Year One 217K USD +11.3%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 207K USD -24.2%
Lessee, Operating Lease, Liability, to be Paid, Year Three 224K USD +1.82%
Deferred Tax Assets, Operating Loss Carryforwards 53M USD +8.18%
Preferred Stock, Shares Issued 119K shares
Preferred Stock, Shares Authorized 10M shares 0%
Lessee, Operating Lease, Liability, to be Paid, Year Four 633K USD -26.1%
Operating Lease, Payments 53K USD +20.5%
Preferred Stock, Shares Outstanding 119K shares
Depreciation, Depletion and Amortization 9K USD -55%
Deferred Tax Assets, Net of Valuation Allowance 198K USD -75.4%
Share-based Payment Arrangement, Expense 2.55M USD -54.2%
Interest Expense 0 USD -100%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%